ArticleAJP reports2026
Rapid Normalization of Amniotic Fluid Index Following Discontinuation of Olmesartan: A Case Report.
Article in AJP reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Angiotensin II receptor blockers (ARBs) are commonly used for hypertension but are contraindicated in pregnancy due to risks of oligohydramnios, renal dysgenesis, and pulmonary hypoplasia from suppression of the fetal renin-angiotensin system. Olmesartan, a frequently prescribed ARB, has a longer receptor binding half-life and higher affinity than other ARBs, producing more potent and sustained antihypertensive effects. Emerging evidence suggests that stopping ARBs during pregnancy may allow recovery of amniotic fluid and renal function. Case: A 30-year-old primigravida with chronic hypertension presented at 24 weeks' gestation while taking olmesartan. Ultrasound revealed anhydramnios with a normal-appearing fetal genitourinary tract. Olmesartan was discontinued and replaced with labetalol. Within 2 weeks, the amniotic fluid index normalized, and subsequent ultrasounds showed sustained recovery. At 34 weeks, she delivered a viable male infant with reassuring renal function and only mild, improving calyceal dilation on postnatal ultrasound. Conclusion: This is, to our knowledge, the first reported case of reversible anhydramnios associated with first- and second-trimester olmesartan exposure. The favorable outcome highlights the potential for reversibility of ARB-related fetopathy with timely cessation. Clinicians should consider serial ultrasound monitoring before recommending termination, as early drug withdrawal may restore amniotic fluid and support normal neonatal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.